Orna Therapeutics
Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.
1 past transactions
ReNAgade Therapeutics
Acquisition in 2024
ReNAgade Therapeutics is a biotechnology company specializing in RNA therapeutics aimed at treating various diseases. The company has developed a comprehensive RNA platform that facilitates coding, editing, and gene insertion, thereby enabling the creation of innovative medications. Utilizing a proprietary CRISPR-Cas9 system, ReNAgade’s technology allows for precise gene editing, which minimizes off-target effects and enhances the long-term efficacy of gene therapies. This approach positions the company to address a wide range of applications within the gene therapy landscape, ultimately making treatments safer and more effective for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.